SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE).

How it works

Osmotic laxative; induces bowel cleansing by retaining water in the intestinal lumen via osmotic effects, increasing intraluminal pressure and stimulating peristalsis.

What the body does with it

Metabolism	Not metabolized; sulfates are renally excreted unchanged.
Excretion	Primarily renal: sulfate ions are excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Half-life	Not applicable as intact drug; component electrolytes have variable half-lives: sulfate ~12-24 hours; potassium and magnesium are actively regulated with redistribution half-lives of minutes to hours.
Protein binding	Negligible (<5%); sulfate and electrolytes do not significantly bind to plasma proteins.
Volume of Distribution	Not applicable as mixture; electrolytes distribute throughout total body water (0.5-0.6 L/kg), sulfate distributes in extracellular fluid (~0.2 L/kg).
Bioavailability	Oral: absorption of sulfate is ~10-30% due to poor intestinal permeability; potassium and magnesium are ~70-90% absorbed.
Onset of Action	Oral: bowel evacuation begins within 1-3 hours; peak effect at 3-6 hours.
Duration of Action	Effect lasts 3-6 hours; colonic cleansing persists until bowel evacuation complete (typically 6-12 hours post-dose).

Classification & Brands

Dosing & administration

Oral: 3 packets (each containing 17.5g sodium sulfate, 3.13g potassium sulfate, and 1.6g magnesium sulfate) dissolved in water as a single dose, or as two doses: first packet in evening, second and third packets next morning. Route: oral. Frequency: single or split dose for colonoscopy preparation.

Dosage form	SOLUTION
Renal impairment	Contraindicated in GFR <30 mL/min/1.73m². For GFR 30-59 mL/min/1.73m²: no dose adjustment recommended, but monitor for electrolyte abnormalities. No data for dialysis patients; avoid use.
Liver impairment	Child-Pugh Class A: no adjustment. Class B: use with caution, monitor electrolytes. Class C: contraindicated due to risk of electrolyte imbalances and encephalopathy.
Pediatric use	Not recommended for pediatric patients. Safety and efficacy not established.
Geriatric use	No specific dose adjustment, but use with caution due to increased risk of electrolyte disturbances, renal impairment, and aspiration. Ensure adequate hydration and monitor electrolytes before and after administration.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE).

Breastfeeding	Unknown if excreted in human milk. Caution advised. M/P ratio not established. Consider risk versus benefit.
Teratogenic Risk	Pregnancy Category C. In first trimester, fetal risks include potential hypocalcemia and hypermagnesemia; in second and third trimesters, risks include fetal hypocalcemia, hypotonia, and respiratory depression. However, no adequate well-controlled studies in pregnant women. Use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Risk of serious fluid and electrolyte disturbances, including hypovolemia and electrolyte abnormalities, which may lead to cardiac arrhythmias, seizures, or renal impairment. Use with caution in patients with renal impairment, heart failure, or electrolyte abnormalities. Not for use in patients with bowel obstruction, perforation, or ileus.

Side Effect Profile

Serious Effects

Absolute Contraindications

Bowel obstruction, ileus, gastrointestinal perforation, gastric retention, toxic colitis, toxic megacolon, known hypersensitivity to sulfates or any component, severe dehydration, and patients with electrolyte abnormalities (e.g., hypermagnesemia, hypernatremia).

Clinical Precautions

Precautions

Monitor for fluid and electrolyte disturbances; ensure adequate hydration. Caution in patients with renal insufficiency, heart failure, ascites, or on medications that affect fluid/electrolyte balance. Risk of arrhythmias, seizures, and renal impairment. Avoid in patients with known hypersensitivity to any component.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE).

How it works

Osmotic laxative; induces bowel cleansing by retaining water in the intestinal lumen via osmotic effects, increasing intraluminal pressure and stimulating peristalsis.

What the body does with it

Metabolism	Not metabolized; sulfates are renally excreted unchanged.
Excretion	Primarily renal: sulfate ions are excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Half-life	Not applicable as intact drug; component electrolytes have variable half-lives: sulfate ~12-24 hours; potassium and magnesium are actively regulated with redistribution half-lives of minutes to hours.
Protein binding	Negligible (<5%); sulfate and electrolytes do not significantly bind to plasma proteins.
Volume of Distribution	Not applicable as mixture; electrolytes distribute throughout total body water (0.5-0.6 L/kg), sulfate distributes in extracellular fluid (~0.2 L/kg).
Bioavailability	Oral: absorption of sulfate is ~10-30% due to poor intestinal permeability; potassium and magnesium are ~70-90% absorbed.
Onset of Action	Oral: bowel evacuation begins within 1-3 hours; peak effect at 3-6 hours.
Duration of Action	Effect lasts 3-6 hours; colonic cleansing persists until bowel evacuation complete (typically 6-12 hours post-dose).

Classification & Brands

Dosing & administration

Dosage form	SOLUTION
Renal impairment	Contraindicated in GFR <30 mL/min/1.73m². For GFR 30-59 mL/min/1.73m²: no dose adjustment recommended, but monitor for electrolyte abnormalities. No data for dialysis patients; avoid use.
Liver impairment	Child-Pugh Class A: no adjustment. Class B: use with caution, monitor electrolytes. Class C: contraindicated due to risk of electrolyte imbalances and encephalopathy.
Pediatric use	Not recommended for pediatric patients. Safety and efficacy not established.
Geriatric use	No specific dose adjustment, but use with caution due to increased risk of electrolyte disturbances, renal impairment, and aspiration. Ensure adequate hydration and monitor electrolytes before and after administration.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE).

Breastfeeding	Unknown if excreted in human milk. Caution advised. M/P ratio not established. Consider risk versus benefit.
Teratogenic Risk	Pregnancy Category C. In first trimester, fetal risks include potential hypocalcemia and hypermagnesemia; in second and third trimesters, risks include fetal hypocalcemia, hypotonia, and respiratory depression. However, no adequate well-controlled studies in pregnant women. Use only if clearly needed.